Comparing Magnetic Resonance Imaging/Spectroscopy Techniques

Sponsor
National Institutes of Health Clinical Center (CC) (NIH)
Overall Status
Terminated
CT.gov ID
NCT00001219
Collaborator
(none)
49,946
1
395.5
126.3

Study Details

Study Description

Brief Summary

Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) are diagnostic tests that allow researchers to look at different chemical properties of tissue. Magnetic resonance imaging and spectroscopy studies can be used to gather or evaluate information about various aspects of patient s bodies or to monitor changes in the biochemistry and physiology of patient s bodies.

Unlike other diagnostic techniques (CT scan and PET scan) MRI and MRS do not use ionizing radiation. Some studies have shown that MRI is more effective at distinguishing normal parts of the anatomy from abnormal anatomy, especially in the brain. MRI has become the diagnostic test of choice for evaluating patient with multiple sclerosis.

The purpose of this study is to evaluate normal volunteers and patients with a variety of diseases with magnetic resonance imaging. Researchers will attempt different magnetic resonance imaging methods and techniques as well as different levels of magnetic strength.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Background:

    MRI is a constantly evolving imaging modality. Pulse sequences are often modified to improve their performance. However, many of these changes have not yet been approved by the FDA and therefore, are not considered standard of care. Some of these sequences require the use of new types of imaging coils, which are also investigational.

    Objectives:

    The major purpose of this protocol is to inform patients undergoing MR scans in the Clinical Center that they be scanned with MRI sequences and/or coils which may or may not be FDA approved and to get the patient s consent for this. This is not a formal research study since specific disease entities and specific pulse sequences are not studied in a systematic way. Rather, the purpose is to give NIH patients access to gradual improvements in MR technology that would otherwise not be available to them.

    Eligibility:

    All patients who, by virtue of the NIH protocol in which they are enrolled, qualify for MRI will be eligible for participation in this protocol.

    Design:

    Up to 99,999 participants will be enrolled in this study.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    49946 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Magnetic Resonance Imaging at 1.5 and 3.0 Tesla
    Actual Study Start Date :
    Jun 18, 1987
    Actual Primary Completion Date :
    Jun 3, 2020
    Actual Study Completion Date :
    Jun 3, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Patients undergoing MRI in the Clinical Center

    All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.

    Outcome Measures

    Primary Outcome Measures

    1. Success of new sequences [10 scan comparison]

      clinically meaningful pulse sequence improvements

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    • All patients undergoing MRI in the Clinical Center.

    • Patients must be able to provide informed consents.

    EXCLUSION CRITERIA:
    • Contraindications to MRI.

    • Inability to understand consent form or consent process and the absence of a suitable guardian.

    • Adults who are or may not be able to consent

    • Patients in whom the scan must be performed quickly, i.e. those patients under anesthesia, anxious patients, those requiring emergency medical care, or others in which it is deemed inappropriate to prolong a study.

    • Refusal to Participate.

    • Pregnant women and fetuses

    • Neonates

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institutes of Health Clinical Center (CC)

    Investigators

    • Principal Investigator: John A Butman, M.D., National Institutes of Health Clinical Center (CC)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Institutes of Health Clinical Center (CC)
    ClinicalTrials.gov Identifier:
    NCT00001219
    Other Study ID Numbers:
    • 870091
    • 87-CC-0091
    First Posted:
    Nov 4, 1999
    Last Update Posted:
    Jun 5, 2020
    Last Verified:
    Jun 1, 2020
    Keywords provided by National Institutes of Health Clinical Center (CC)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 5, 2020